FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 131 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept Patient Guide in Testicular Cancer Now Available Also in German MOST POPULAR Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... September 1, 2020 Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... February 12, 2020 Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... September 18, 2019 Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... March 23, 2022 Load more HOT NEWS Why is Colorectal Cancer Rising Rapidly among Young Adults? FDA Approves Idecabtagene Vicleucel for Multiple Myeloma Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations
